NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Receives Average Recommendation of “Moderate Buy” from Analysts

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) has earned an average recommendation of “Moderate Buy” from the six ratings firms that are currently covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell rating, one has given a hold rating and four have given a buy rating to the company. The average twelve-month price target among brokers that have issued ratings on the stock in the last year is $36.50.

Several brokerages recently weighed in on NRXP. D. Boral Capital reaffirmed a “buy” rating and set a $34.00 price objective on shares of NRx Pharmaceuticals in a research report on Tuesday, December 2nd. Zacks Research raised shares of NRx Pharmaceuticals to a “hold” rating in a research report on Wednesday, September 10th. Wall Street Zen raised NRx Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Sunday, November 23rd. BTIG Research reiterated a “buy” rating and issued a $25.00 price objective on shares of NRx Pharmaceuticals in a research note on Wednesday, December 3rd. Finally, HC Wainwright reissued a “buy” rating and set a $40.00 price objective on shares of NRx Pharmaceuticals in a research report on Tuesday, December 16th.

NRx Pharmaceuticals Price Performance

Shares of NRXP stock opened at $2.71 on Friday. The firm’s 50-day simple moving average is $2.47 and its 200-day simple moving average is $2.81. NRx Pharmaceuticals has a 1-year low of $1.47 and a 1-year high of $6.01. The firm has a market cap of $80.22 million, a P/E ratio of -1.15 and a beta of 1.62.

NRx Pharmaceuticals (NASDAQ:NRXP) last released its quarterly earnings data on Friday, November 14th. The company reported ($0.18) EPS for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.07). The firm had revenue of $0.24 million during the quarter, compared to the consensus estimate of $6.83 million. Analysts expect that NRx Pharmaceuticals will post -1.75 earnings per share for the current fiscal year.

Institutional Investors Weigh In On NRx Pharmaceuticals

Several hedge funds have recently modified their holdings of NRXP. Anson Funds Management LP grew its stake in shares of NRx Pharmaceuticals by 535.1% in the first quarter. Anson Funds Management LP now owns 1,179,061 shares of the company’s stock worth $2,417,000 after acquiring an additional 993,401 shares during the last quarter. Vanguard Group Inc. boosted its holdings in NRx Pharmaceuticals by 18.3% in the 3rd quarter. Vanguard Group Inc. now owns 534,956 shares of the company’s stock valued at $1,765,000 after purchasing an additional 82,781 shares during the period. Geode Capital Management LLC boosted its holdings in NRx Pharmaceuticals by 27.9% in the 2nd quarter. Geode Capital Management LLC now owns 172,255 shares of the company’s stock valued at $562,000 after purchasing an additional 37,598 shares during the period. Two Sigma Investments LP grew its position in NRx Pharmaceuticals by 66.4% in the 3rd quarter. Two Sigma Investments LP now owns 52,332 shares of the company’s stock worth $173,000 after purchasing an additional 20,880 shares during the last quarter. Finally, AdvisorShares Investments LLC increased its holdings in shares of NRx Pharmaceuticals by 29.7% during the 3rd quarter. AdvisorShares Investments LLC now owns 342,136 shares of the company’s stock worth $1,129,000 after purchasing an additional 78,339 shares during the period. 4.27% of the stock is owned by institutional investors.

NRx Pharmaceuticals Company Profile

NRx Pharmaceuticals, Inc is a clinical-stage specialty biopharmaceutical company focused on the development and repurposing of small-molecule therapeutics for central nervous system and rare disease indications. The company’s research strategy centers on advancing compounds with established safety profiles into new neurological and inflammatory conditions, leveraging translational science and biomarker-driven trial design to accelerate clinical development. NRx’s pipeline includes Ifenprodil, an NMDA receptor antagonist in investigation for acute respiratory distress syndrome and inflammatory muscle disorders, as well as investigational formulations targeting depressive and cognitive disorders.

Since securing global rights to its lead assets, NRx has initiated multiple proof-of-concept studies in the United States and Europe, collaborating with academic institutions and clinical research organizations to evaluate safety and efficacy across a range of indications.